274
Participants
Start Date
November 30, 2004
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
Chrysalin
Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
Chrysalin
Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
Chrysalin
Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
Chrysalin
Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
Placebo
Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
OrthoLogic, Tempe
Lead Sponsor
Capstone Therapeutics
INDUSTRY